Nov 12, 2024, 01:00 AM by User Not Found

Bio-IT World | In recent research, scientists at the University of Arizona have developed a diagnostic tool, the MeCo Score, which evaluates metastatic risk in early-stage breast cancer by analyzing how cancer cells respond to the stiffness of surrounding tissue. This tool leverages RNA sequencing data from tumor samples to identify a "mechanical conditioning" (MeCo) signature, giving insights into cancer cell adaptations within the tumor microenvironment.

Nov 11, 2024, 08:25 AM by

AppOmni, the leader in SaaS security today announced a significant partnership that combines the company’s Zero Trust Posture Management (ZTPM) solution with Cisco’s Security Service Edge (SSE) technology suite to enable zero trust principles at the application layer in Security-as-a-Service (SaaS) applications.

Nov 8, 2024, 01:00 AM by User Not Found

Bio-IT World | For AI and data-driven drug discovery to have a tangible impact on R&D success, a change in the culture is as important as any investment at a data, model, and validation level. Until quite recently, the perceived value of AI in drug discovery and development failed to match the hype.

Nov 7, 2024, 10:45 AM by

UK-based pharma strategic consultancy, The MAP Group has acquired market access and pricing consultancy, SKC Beratungsgesellschaft mbH as it continues to expand internationally.

Nov 7, 2024, 01:00 AM by User Not Found

Bio-IT World | This week at the American Society of Human Genetics meeting, Pacific Biosciences unveiled both its new SPRQ chemistry—pronounced “spark”— and its newest sequencing platform, Vega, a desktop, long-read sequencer with all the compute on board. Also it’s pink.

Nov 6, 2024, 08:27 AM by

Oxford Nanopore announced a landmark strategic partnership that brings together Genomics England, UK Biobank, and NHS England to enable genomics-based translational research and accelerate the development and adoption of Oxford Nanopore’s ground-breaking genomics technology in the NHS.

Nov 4, 2024, 08:55 AM by

Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, and Domainex, a multi-award winning provider of integrated, pre-clinical drug discovery services, today announced that Domainex is the first contract research organization (CRO) to have installed the eProtein Discovery system and offer protein production services using the technology.

Nov 4, 2024, 01:00 AM by User Not Found

Bio-IT World | The traditional LDL and HDL cholesterol tests may soon be obsolete as new research suggests they provide an incomplete view of heart health compared to other lipid molecules circulating in the blood. This shift stems from a recent study led by Dr. Cristina Legido-Quigley, a systems medicine expert at King’s College London and Steno Diabetes Centre, which analyzed lipids in children with obesity.

Nov 1, 2024, 08:05 AM by

Endor Labs, the leader in open source software security, has once again been selected to the prestigious Fortune Cyber 60 list, the second consecutive year it has received this recognition.

Nov 1, 2024, 08:05 AM by

PathAI, a leader in digital and AI-powered pathology solutions, and VIZIA Diagnostics, a GI- specialized pathology laboratory based in Alpharetta, Georgia, have announced that VIZIA has adopted PathAI’s AISightⓇ1 Image Management System (IMS) and AI technology to advance the precision and operational efficiency of its pathology services.

Nov 1, 2024, 08:05 AM by

Nov 1, 2024, 08:05 AM by

Nov 1, 2024, 08:05 AM by

Oct 31, 2024, 01:00 AM by User Not Found

Bio-IT World | Harvard scientists have succeeded in using artificial intelligence (AI) to identify promising drug candidates for diseases for which there are no examples of successful treatment. The graph foundation model, known as TxGNN, opens untold opportunities to repurpose drugs for the thousands of diseases afflicting small populations and exacting a huge toll in terms of both economics and human suffering.

Oct 30, 2024, 07:21 AM by

Phreesia announced that it has achieved Oracle Validated Integration with Oracle Health Electronic Health Record (EHR) Expertise for its integration of the Phreesia platform.

Oct 30, 2024, 07:21 AM by

Today, Quris-AI announced the acquisition of Nortis. Nortis' high-quality microphysiology systems (MPS) database and ability to accurately mimic human biology provided a unique value proposition, perfectly aligning with Quris-AI's mission to improve drug safety prediction. Nortis’s Kidney-on-Chip models, which set new standards for in-vitro drug testing and personalized medicine, will be combined with Quris-AI’s advanced machine learning models and patented patient-on-chip system that can predict a real human body’s reaction to drugs and eliminate potentially harmful drug candidates earlier in the drug development process.

Oct 30, 2024, 07:21 AM by

VALANX Biotech (VALANX) and Fina Biosolutions LLC (FinaBio) today announced the signing of a joint IP and licensing agreement. The companies will launch ClickCRM™, a ready-to-conjugate version of CRM197, an antigenic carrier protein used for making conjugate vaccines. The new product enables the rapid, high-efficiency conjugation of carrier proteins to polysaccharide antigens for the generation of conjugate vaccines.

Oct 30, 2024, 07:21 AM by

Sapio Sciences today announced it has strengthened its long-term relationship with Amazon Web Services, Inc. (AWS) through the integration of AWS Bedrock with the Sapio Platform. This integration makes advanced generative AI models readily accessible to scientists and researchers within the same secure AWS environment that already powers Sapio’s Laboratory Information Management System (LIMS) and Electronic Lab Notebook (ELN).

Oct 30, 2024, 01:00 AM by User Not Found

Bio-IT World | Modifi Biosciences has been acquired by Merck; Sapio Sciences announces the addition of new immunogenicity bioanalysis features to its industry-leading lab informatics platform; and more.

Oct 29, 2024, 08:24 AM by

Takara Bio Europe has announced the expansion of its Gothenburg facility, with the addition of a custom manufacturing lab. This new facility now offers a comprehensive array of customised molecular biology products, including PCR and qPCR enzymes, servicing the molecular biology needs of academic researchers, diagnostic labs, and biotech companies across EMEA, producing up to 600,000 reactions per week. With these expanded capabilities, customers can expect faster deliveries, personalised service, and real-time access to technical expertise, ensuring projects move forward efficiently while supporting sustainability goals through reduced carbon emissions.